Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Clinical trial NCT07263360 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07263360
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-01
- Primary completion
- 2028-03-31
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.